Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast

Annals of Allergy, Asthma and Immunology

Volumn 92, Issue 5, 2004, Pages 523-529

  Orsini, Lucinda ^a   Limpa Amara, Sasigaant ^b   Crown, William H ^a   Stanford, Richard H ^c   Kamal, Khalid ^d  

^a MEDSTAT GROUP   (United States)

^b Mathematics Policy Research   (United States)

^c GLAXOSMITHKLINE   (United States)

^d WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; MONTELUKAST; SALMETEROL; ACETIC ACID DERIVATIVE; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; FLUTICASONE; QUINOLINE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; COMPARATIVE STUDY; ECONOMICS; STATISTICS; TREATMENT OUTCOME;

ACETATES; ADULT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; QUINOLINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 3042540366     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61759-0     Document Type: Article

References (29)

1. Healthy People 2010. Available at: http://www.health.gov/ healthypeople/Document/HTML/Volume2/ 24Respiratory.htm#_Toc489704825. Accessed August 20, 2002.
2. NCHS, Health E Stats, Asthma. Available at: http://www.cdc.gov/ nchs/products/pubs/pubd/hestats/asthma/asthma.htm. Accessed April 11, 2002.
3. Pappas G, Hadden WC, Kozak LJ, Fisher GF. Potentially avoidable hospitalizations: inequalities in rates between US socioeconomic groups. Am J Public Health. 1997;87:811-816.
4. National Heart, Lung, and Blood Institute. Data Fact Sheet: Asthma Statistics. Bethesda, MD: National Institutes of Health, Public Health Service; 1999.
5. Stempel DA, Pinto L, Stanford RH. The risk of hospitalization in patient with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonist. J Allergy Clin Immunol. 2002;10:39-41.
6. Stempel DA, Neyer JW, Stanford RH, Yancey SW. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol. 2001;107:94-98.
7. Sin DD, Man SFP. Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch Intern Med. 2002;162:1591-1595.
8. National Heart, Lung, and Blood Institute. Practical Guide for the Diagnosis and Management of Asthma: Based on the Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; October 1997. NIH publication 97-4053.
9. The National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002 (Updated the Expert Panel Report 2). Bethesda, MD: National Heart, Lung, and Blood Institute; July 2002. NIH publication 02-5075.
10. Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol. 2000;105: 1123-1129.
11. Kim KT, Ginchansky EJ, Friedman BF, et al. Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy. Ann Allergy Asthma Immunol. 2000;85:398-406.
12. Stempel DA, Mauskopf J, McLaughlin T, Yazdani C, Stanford RH. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med. 2001;95:227-234.
13. Lamb H, Culy CR, Faulds D. Inhaled fluticasone propionate: a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics. 2000;18:487-510.
14. Busse W, Wolfe J, Storms W, et al. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. J Fam Pract. 2001;50:595-602.
15. Ducharrme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ. 2003;3:26.
16. Berndt ER, Bir A, Busch SH, Frank RG, Normand SL. The medical treatment of depression, 1991-1996: productive inefficiency, expected outcome variations, and price indexes. J Health Econ. 2002;21:373-396.
17. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284: 1655-1663.
18. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963-971.
19. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850-860.
20. Duan N. Smearing estimate: a nonparametric retransformation method. Am Stat Assoc. 1983;78:605-610.
21. Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A, Marquis MS. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987;77:251-277.
22. Duan N, Manning W, Morris C, Newhouse J. A comparison of alternative models for the demand for medical care. J Business Econ Stat. 1983;2:115-126.
23. Halpern MT, Khan ZM, Stanford RH, Spayde KM, Golubiewski M. Asthma: resource use and costs for inhaled corticosteroid vs leukotriene modifier treatment- a meta-analysis. J Fam Pract. 2003;52:382-389.
24. Crown W, Obenchain R, Englehart L. The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. Stat Med. 1998;17:1943-1958.
25. Rosenbaum P, Rubin D. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524.
26. Heckman JJ. The common structure of statistical models of truncation, sample selection and limited dependent variables and a simple estimator for such models. Ann Econ Soc Measure. 1976;5:475-492.
27. Blanc PD, Jones M, Besson C, Katz P, Yelin E. Work disability among adults with asthma. Chest. 1993;104:1371-1377.
28. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med. 1992;326:862-866.
29. Barnes PR, Jonsson B, Kilm JB. The costs of asthma. Eur Respir J. 1996;9:636-642.